Should Investors Follow The Big Tech Exodus by ARK?
πππIn March 2026, Cathie Wood's ARK Invest has executed a massive pivot, dumping nearly USD 100 million in Big Tech in a single 48 hour window. This isn't just a trim. It is a full blown "vibe shift" that has the market wondering if the AI coronation is over, or is ARK looking for a new king.
The Big Tech Exodus: March 26 to 27 2026
ARK has been aggressively slashing its exposure to the "Magnificent" winners that fueled 2025's rally:
The Heavy Hitters: Parted with USD 41 million in Meta Platforms and USD 26 million in NVIDIA.
The Semiconductor Selloff: Executed significant sales in AMD - USD 7.8 million and TSMC - USD 5.1 million, citing production bottlenecks and overstretched supply chains.
The Broader Cut: Trimmed positions in Alphabet - USD 2.5 million and redirected capital away from Broadcom and Netflix.
Why the Rotation?
Valuation Fatigue: With the flagship $ARK Innovation ETF(ARKK)$
Geopolitical Jitters: Rising uncertainty in the Middle East and Iran has spiked oil prices, fueling inflation fears that typically hit high growth tech first.
The "New AI" Hunt: ARK isn't leaving AI. It is just moving from the "builders" (chips) to the "users". ARK has aggressively loaded up on Tempus AI, a healthcare tech play, making it one of its largest holdings.
What is ARK Buying Now?
Apart from the heavy accumulation of Tempus AI, ARK has recently been loading up on:
Circle Internet Group (CRCL)$Circle Internet Corp.(CRCL)$ : ARK recently made a massive USD 16 million purchase as the stock stumbled 20%. It has quickly ascended to become one of its top 3 holdings in the flagship ARKK fund.
GeneDx Holdings (WGS): A steady accumulation trend continues here, with recent buys totalling USD 250,706 across the Innovation and Genomics funds.
Arcturus Therapeutics (ARCT): Cathie Wood recently added this during the March bargain hunt.
Tesla $Tesla Motors(TSLA)$
Tempus AI $Tempus AI(TEM)$
Tempus AI is essentially Cathie Wood's new Northstar for 2026.
Tempus' Mission: It is a precision medicine company that uses AI to liberate healthcare data from silos. Think of it as an operating system for the human body. Tempus analyses massive datasets to help doctors tailor oncology treatments to a patient's specific genetic profile.
Why ARK Loves Tempus: Tempus has just expanded its Big Pharma reach, partnering with Daiichi Sankyo and Merck to identify which patients will actually respond to new cancer therapies. In a world of "guess and check" medicine, Tempus is trying to bring "search and find" accuracy.
The Numbers: ARK poured USD 28 million into Tempus in early 2026 alone. While Tempus faces financial challenges like negative margins, its revenue grew over 80% year over year in late 2025.
ARKK Top 3 Holdings As Of March 27 2026
1. Tesla (TSLA) at 10.08%
2. CRISPR Therapeutics (CRSP) at 5.91%.
3. Circle Internet Group (CRCL) at 5.60%.
Should Investors Follow ARK?
To follow Cathie Wood's ARK into the 2026 Big Tech Selloff, is to embrace a special kind of financial adrenaline. Whether you should follow her depends entirely on whether you view her as a visionary prophet or a high stakes gambler.
Why You Should Follow ARK: The Alpha Hunter
The Early Bird Edge: ARK doesn't buy what is working now. It buys what might rule the world in 2030. If you believe that Tempus AI is the "Nvidia of Biology" or that Circle Internet is the future of the global financial plumbing, Cathie Wood is your fearless leader.
Concentrated Conviction: When ARK likes a stock, it loves it. ARK doesn't do "benchmark hugging". If its thesis on Tesla's Robotaxis or CRISPR's gene editing finally hits mainstream, the gains could make the Nvidia rally look like a warm up.
Transparency: You get to see ARK's trades every day. No other fund shows you their trades in real time. It is like a free master class in disruptive thinking or a cautionary tale, depending on the day.
Why You Shouldn't Follow ARK: The Volatility Trap
The "Exit" Problem: ARK's strategy works beautifully ....until it doesn't. When it dumps USD 100 million in Big Tech, it often does it right before a relief rally. When it buys "bargains" like Circle, it sometimes catches falling knives with both hands.
The Fees vs The Feels: With a 0.75% expense ratio, you are paying a premium for a ride that has seen ARKK drop significantly while the boring S&P 500 (SPY) quietly hit new highs.
Tax Headache: The constant buying and selling like this week's Meta and Nvidia purge, can create a whirlwind of capital gains distributions for investors, even if the price is down.
Concluding Thoughts
Following ARK in 2026, is like being in a long distance relationship with a hurricane. It is thrilling. It can be expensive and you are never quite sure if you are going to wake up in a mansion or a storm cellar.
Cathie Wood has just dumped the Magnificent 7 like a bad Tinder date and swiped right on Genomics and Stablecoin infrastructure.
If you have the investor temperament of a Zen monk and the risk appetite of a Las Vegas local, then follow her into the Tempus AI wilderness.
But if you are the type of person who checks his portfolio every time oil ticks up a cent, maybe stick to the 2.5% CPF OA or a boring index fund like SPY.
ARK isn't a portfolio strategy. It is a belief system.
If you are looking for a safe haven, look elsewhere. But if you are looking to disrupt your sleep schedule in exchange for a shot at the next 10x moonshot, Cathie Wood is holding the keys to the rocket ship.
Just remember: Sometimes the rocket lands on Mars and sometimes it lands in the ocean. Either way, it is never a boring flight.
@Tiger_comments @Tiger_SG @TigerStars @TigerClub @CaptainTiger
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
